A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
74actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-27 | actual | When the study began enrolling |
| Primary completion | 2025-10-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-21 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BMS-986419
- Drug: BMS-986419 Matching Placebo
- Drug: Moxifloxacin
- Drug: Moxifloxacin Matching Placebo
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants with Non-serious Adverse Events (NSAEs)
measured Up to approximately Day 42
Part 1: Number of Participants with Serious Adverse Events (SAEs)
measured Up to approximately Day 42
Part 1: Number of Participants with AEs Leading to Discontinuation
measured Up to approximately Day 42
Part 1: Number of Participants With AEs of Special Interest (AESI)
measured Up to approximately Day 42
Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities
measured Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities
measured Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
measured Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Columbia-Suicide Severity Rating Scale (C-SSRS) Abnormalities
measured Up to approximately Day 21
Part 1: Number of Participants With Clinically Significant Neurological Examination Abnormalities
measured Up to approximately Day 21
Part 1: Number of Participants With Physical Examination Abnormalities
measured Up to approximately Day 21
Part 2: ΔQTc: Change From Baseline in Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QT interval (QTc)
measured Up to approximately Day 15
Part 2: ΔΔQTc: Placebo-corrected Change From Baseline QTc Plasma Concentration of BMS-986419 on Cardiac Repolarization Expressed by QTc
measured Up to approximately Day 15
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed